

09/623006

533

PCT/PTO 24 AUG 2000

Page 1 of 1

PTO FORM 4/92

FORM PTO-1449

Docket No.: 10738-17

Serial No.: PCT/US99/06580

LIST OF PATENTS AND PUBLICATIONS

Applicant: David Y. Hui et al.

FOR INFORMATION DISCLOSURE STATEMENT

File Date: March 25, 1999 Group:

Exam. Init.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS
Rm	5 7 9 2 9 0 2	Aug. 11, 1998	Benoit et al.	800	2
Rm	5 8 5 1 5 2 1	Dec. 22, 1998	Branellec et al.	424	93.2
Rm	5 8 6 6 5 5 1	Feb. 2, 1999	Benoit et al.	514	44

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS
WO 95 2 5 7 4 9	Sept. 28, 1995	PCT		
2 6 8 6 6 0 5	Jan. 27, 1992	FR		
WO 99 3 5 2 4 1	July 15, 1999	PCT		

## OTHER ART (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

Rm	Duverger et al., Protection Against Atherogenesis in Mice Mediated by Human Apolipoprotein A-IV; Science, Vol. 273, 16 August 1996, pgs. 966-968.
Rm	Carew et al., Antitherogenic effect of probucol unrelated to its hypocholesterolemic effect; Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 7725-7729, November 1987, Medical Sciences, pgs. 7725-7729.
Rm	Cohen et al., Reduced Eortic Lesions and Elevated High Density Lipoprotein Levels in Transgenic Mice Overexpressing Mouse Apolipoprotein A-IV; The Journal of Clinical Investigation, Volume 99, Number 8, April 1997, 1906-1916
Rm	Qin et al., Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation; 1998 The American Physiological Society, pgs. H1836-H1840.

EXAMINER RITA MITA DATE CONSIDERED

1/9/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#587034v1 &lt;CINTI&gt; -IDS-10738-17.wpd

\* LINED THROUGH - NO ENGLISH LANG. TRANSLATION.